Literature DB >> 30171383

Evaluation of atrial septal defects with 4D flow MRI-multilevel and inter-reader reproducibility for quantification of shunt severity.

Raluca G Chelu1,2, Michael Horowitz3, Dominica Sucha4, Isabella Kardys5, Delphine Ingremeau6, Shreyas Vasanawala7, Koen Nieman8,9,7,10, Jean-Francois Paul6, Albert Hsiao3.   

Abstract

PURPOSE: With the hypothesis that 4D flow can be used in evaluation of cardiac shunts, we seek to evaluate the multilevel and interreader reproducibility of measurements of the blood flow, shunt fraction and shunt volume in patients with atrial septum defect (ASD) in practice at multiple clinical sites.
MATERIALS AND METHODS: Four-dimensional flow MRI examinations were performed at four institutions across Europe and the US. Twenty-nine patients (mean age, 43 years; 11 male) were included in the study. Flow measurements were performed at three levels (valve, main artery and periphery) in both the pulmonary and systemic circulation by two independent readers and compared against stroke volumes from 4D flow anatomic data. Further, the shunt ratio (Qp/Qs) was calculated. Additionally, shunt volume was quantified at the atrial level by tracking the atrial septum.
RESULTS: Measurements of the pulmonary blood flow at multiple levels correlate well whether measuring at the valve, main pulmonary artery or branch pulmonary arteries (r = 0.885-0.886). Measurements of the systemic blood flow show excellent correlation, whether measuring at the valve, ascending aorta or sum of flow from the superior vena cava (SVC) and descending aorta (r = 0.974-0.991). Intraclass agreement between the two observers for the flow measurements varies between 0.96 and 0.99. Compared with stroke volume, pulmonic flow is underestimated with 0.26 l/min at the main pulmonary artery level, and systemic flow is overestimated with 0.16 l/min at the ascending aorta level. Direct measurements of ASD flow are feasible in 20 of 29 (69%) patients.
CONCLUSION: Blood flow and shunt quantification measured at multiple levels and performed by different readers are reproducible and consistent with 4D flow MRI.

Entities:  

Keywords:  4D flow MRI; Atrial septal defect; Multiple measurements

Mesh:

Year:  2018        PMID: 30171383      PMCID: PMC6424937          DOI: 10.1007/s10334-018-0702-z

Source DB:  PubMed          Journal:  MAGMA        ISSN: 0968-5243            Impact factor:   2.310


Introduction

Atrial septal defects (ASD) are one of the most common congenital heart defects with an estimated prevalence of 1.6 per 1000 live births [1]. Most prevalent are ostium secundum defects followed by ostium primum and sinus venosus defects [2]. Partial anomalous pulmonary venous connections (PAPVRs) are often associated with ASD, especially with sinus venosus defects. When repaired at a young age, patients with ASD have a life expectancy similar to the general population [3, 4]. Left untreated, patients with large ASD gradually develop pulmonary hypertension, reversal of the left-to-right shunt and eventually right heart failure. In clinical practice, ASD closure is considered for patients with a shunt fraction greater than 1.5 [2]. Multiple imaging modalities are used to detect and delineate these anatomic defects. Transthoracic echocardiography (TTE) is used as a primary screening modality. However, associated pathologies such as PAPVR are more difficult to identify with TTE. When TTE is inconclusive, transesophageal echocardiography (TEE) may be helpful [5]. Alternatively, computed tomography (CT) and magnetic resonance imaging (MRI) are increasingly used. MRI has shown its incremental value in congenital heart disease (CHD) [6] and ASD in particular [7]. MRI is the gold standard for noninvasive quantification of right heart function and shunt fraction [8, 9]. It may detect intracardiac shunting and additional findings including PAPVR [10]. However, it is performed with numerous breath-holds and relatively long examination times, which may be challenging for cardiac patients. A promising and rapidly evolving MRI technique is 4D flow imaging, a volumetric, free-breathing acquisition technique of flow velocity data with simultaneous assessment of anatomic structures [11]. The 4D flow MRI allows for flow quantification at any level within the acquired field of view and calculation of cardiac volumes and biventricular function [12-14]. A few studies have evaluated the use of 4D flow MRI for visualization and quantification of cardiac shunts [15-17]. It is not yet clear, however, whether this technique is robust across the range of imaging parameters that might be used in the clinical environment because of differences in body habitus or equipment. In the clinical setting, there may be heterogeneity in imaging techniques because of local preferences or needs for imaging parameters such as the signal-to-noise ratio (SNR), spatial resolution, scanning time, velocity-encoding speed (Venc), available equipment, field strengths (1.5 T, 3 T) and patient body habitus. A previous paper showed that it is possible to measure venous flow even when using high Venc [18]. However, uncertainty remains about whether this technique is applicable outside of the research setting. As this technology has recently become more broadly clinically available, we seek to determine in this study whether 4D flow can robustly be used for the evaluation of cardiac shunts at different levels of the vascular tree using 4D flow data acquired across multiple centers—specifically measurements of the blood flow, shunt fraction and shunt volume.

Methods

Study design

Cardiac MRI examinations including 4D flow were gathered from four academic centers in the US and Europe in patients referred for evaluation of ASD between December 2014 and January 2017. In three centers, 4D flow was performed as part of the clinical protocol and retrospectively included in this study. Informed consent was waived by the local IRB. In the remaining center, patients were prospectively enrolled and signed informed consent for an MRI including 4D flow. The study protocol was compliant with Declaration of Helsinki and received approval from each local medical ethics committee.

4D flow acquisition

At each center, 4D flow MRI acquisition protocols were optimized based on locally available equipment, medications, and clinical requirements. The retrospectively gated 4D flow acquisition was performed using clinical MRI scanners (69% at 1.5 T, 31% at 3 T) (GE Healthcare, Milwaukee, WI, USA) after administration of a gadolinium-based contrast agent. Scan time ranged between 7.46 and 14.75 min (median 10.75 min). All imaging parameters are presented in Table 1.
Table 1

Scanning details

Center 1 (n = 4)Center 2 (n = 9)Center 3 (n = 8)Center 4 (n = 8)Total (n = 29)
Field strength (T)1.5 T (100%)3 T (100%)1.5 T (100%)1.5 T (100%)1.5 T (69%)3 T (31%)
Contrast agentGadobutrol (100%)Gadofosveset trisodium (67%), gadobenate dimeglumine (33%)Gadoterate meglumine (50%), gadobenate dimeglumine (50%)Gadofosveset trisodium (37%), gadobenate dimeglumine (63%)Gadofosveset trisodium (14%), gadoterate meglumine (31%), gadobutrol (14%), gadobenate dimeglumine (41%)
Resolution acquired (mm)(1.8– 2.0) × (2.1–2.4) × 2.8(1.3–2.0) × (1.4–2.4) × (2.4–3.2)(1.4–1.8) × (2.3–2.8) × 2.6(1.0–1.8) × (1.4–2.2) ×  3.0(1.3–2.0) × (1.4–2.8) × (2.4–3.2)
Resolution reconstructed (mm)(1.8–2.0) × (2.1–2.4) × 1.4(1.3–2.0) × (1.3–2.2) × (1.2–1.6)(1.4–1.8) × (2.3–2.8) × 1.3(1.0–1.4) × (1.4–1.8) × 1.5(1.3–2.0) × (1.3–2.2) × (1.2–1.6)
Temporal resolution (ms)a61.4–62.461.2–81.8+51.6–76.349.3–83.249.3–83.2
Heart rate64–7266–8055–10348–7748–103
Sinus rhythm100%100%100%75%93%
Venc (cm/s)180–200150–250200–500250150–500
Scanning time (min)10.42–11.5810.75–14.757.46–14.757.46–10.957.46–14.75

Values are ranges (minimum–maximum)

T Tesla, HR heart rate, venc velocity encoding value

aIn four patients, data were not available

Scanning details Values are ranges (minimum–maximum) T Tesla, HR heart rate, venc velocity encoding value aIn four patients, data were not available

Post-processing

Data were analyzed using dedicated post-processing software (Arterys Inc, San Francisco, CA). Semiautomatic eddy-current correction was applied [19]. Data were visualized, interpreted for the presence of ASD and classified according to type of septal defect. To evaluate consistency of the data across the vascular tree, shunt quantification was performed at multiple levels, as described below. Further, to evaluate intraobserver reproducibility, background correction and measurements were done by two readers independently (with 4 and 1 year of experience with 4D flow).

ASD visualization and classification

To detect and visualize the ASDs, volumetric data sets were reformatted in multiple orientations using several rendering techniques: color-coded velocity overlay, vector-velocity overlay, and streamlines (Fig. 1). ASDs were classified according to international guidelines [2, 5]. To visualize primum and secundum ASDs, the atrial septum was examined in short and long axis (Supplementary Fig. 1). Furthermore, to evaluate the presence of sinus venosus ASD, the superior and inferior cavo-atrial junctions were visualized. The coronary sinus was carefully assessed for detection of unroofed coronary sinus (Supplementary Fig. 2). In addition, streamlines were created from regions of interest in the pulmonary veins to further emphasize the flow across the atrial septum (Fig. 1). Incidental findings including the presence of a bicuspid aortic valve (BAV) and PAPVR were also documented.
Fig. 1

Multiple rendering techniques for ASD visualization. Color velocity overlay helps to identify the shunt in a frame-by-frame approach, but does not show flow directionality a. Flow direction is emphasized with vector overlay b. Streamlines help to track the flow that comes from pulmonary veins to the left atrium. In case of an atrial septum defect, the blood will cross to the right atrium and right ventricle. Ra right atrium, rv right ventricle, la left atrium, lv left ventricle, SVC superior vena cava

Fig. 2

Levels of flow and shunt measurement. Systemic a and pulmonic b blood flows were measured at three different levels. Systemic flow a was measured at the aortic valve level [1], ascending aorta level [2] and as sum (3 = 3a + 3b) of the flow of the superior vena cava above the azygos vein (3a) and descending aorta (3b). When present, left persistent superior vena cava flow was added to the sum of SVC and descending aorta. Pulmonic flow b was measured at the pulmonary valve level [1], main pulmonary artery level [2] and as the sum of the right (3a) and left pulmonary artery flow (3b). Ventricular stroke volumes were calculated using magnitude images c. Additionally, shunt volumes were measured at the ASD level by septal tracking d

Multiple rendering techniques for ASD visualization. Color velocity overlay helps to identify the shunt in a frame-by-frame approach, but does not show flow directionality a. Flow direction is emphasized with vector overlay b. Streamlines help to track the flow that comes from pulmonary veins to the left atrium. In case of an atrial septum defect, the blood will cross to the right atrium and right ventricle. Ra right atrium, rv right ventricle, la left atrium, lv left ventricle, SVC superior vena cava Levels of flow and shunt measurement. Systemic a and pulmonic b blood flows were measured at three different levels. Systemic flow a was measured at the aortic valve level [1], ascending aorta level [2] and as sum (3 = 3a + 3b) of the flow of the superior vena cava above the azygos vein (3a) and descending aorta (3b). When present, left persistent superior vena cava flow was added to the sum of SVC and descending aorta. Pulmonic flow b was measured at the pulmonary valve level [1], main pulmonary artery level [2] and as the sum of the right (3a) and left pulmonary artery flow (3b). Ventricular stroke volumes were calculated using magnitude images c. Additionally, shunt volumes were measured at the ASD level by septal tracking d

Quantification of flow and of shunt

Management of ASD is mostly driven by the severity of cardiac shunting, defined by the pulmonary (Qp) and systemic (Qs) blood flow ratio [2, 5]. Three levels were used to obtain Qp and Qs flow: (1) valve, (2) main artery and (3) periphery (Fig. 2). The valve and vessels were tracked and “contoured” throughout the entire cardiac cycle [19]. Shunt fractions (Qp/Qs) were calculated for each level in all patients. Alternatively, ventricular stroke volumes may be used for shunt fraction calculation, provided that no significant (≤ 20%) valve insufficiency is present. The study population was screened for valvular insufficiency, which was quantified if detected. In the subset of patients with no significant valvular insufficiency, the shunt fraction was calculated additionally using the right ventricular (RVSV) and left ventricular (LVSV) stroke volume ratio. For this, end-diastolic and end-systolic ventricular volumes were segmented from the 4D flow magnitude anatomic images [20]. Lastly, shunt volumes were measured at the atrial level by tracking the atrial septum (Fig. 2). Indirect shunt volume quantification was obtained by subtracting systemic from pulmonary blood flow (Qp–Qs).

Statistics

Statistical analysis was performed with SPSS software version 21 (IBM, New York, USA) and GraphPad Prism 4 Project (San Diego, CA, USA). Categorical variables are presented as number and percentages and continuous variables as mean (± standard deviation) or median (minimum-maximum). Correlation between measurements at different levels was evaluated using Spearman’s (rho) coefficient for nonparametric data, and agreement was analyzed with Bland-Altman plots [21]. The Spearman rho coefficient was classified as “very weak” for values of 0.00–0.19, “weak” for 0.20–0.39, “moderate” for 0.40–0.59, “strong” for 0.60–0.79 and “very strong” for 0.80–1.0 [22]. Interobserver reliability was assessed by intraclass correlation coefficient (ICC).

Results

Study population

Four-dimensional flow MRI examinations from 30 patients with ASD were gathered from the four academic centers. One nondiagnostic examination was excluded. (Supplementary Fig. 3). Mean age was 43 (± 17) years, and 11 (38%) patients were male. Six patients had two ASDs, and one patient had four ASDs. Of the 38 ASDs, 26 (68%) were classified as secundum, 4 (11%) primum and 8 (21%) sinus venosus [6 at the SVC level, 1 at the inferior vena cava (IVC) level and 1 unroofed coronary sinus]. Additional findings included PAPVR (n = 2) and BAV (n = 5).

Correlation of 4D blood flow and stroke volume measurements

Median Qp was 8.5 l/min (4.4–20.2 l/min) at the main pulmonary artery level; 8.6 l/min (3.2–20.3 l/min) at the pulmonary valve level and 8.7 l/min (4.4–19.9 l/min) at the pulmonary branch level. Median cardiac output measured from RVSV was 9 l/min (4.6–20.0 l/min). The correlations between Qp measurements performed at different levels were classified as very strong (Spearman’s rho = 0.885–0.886) (Fig. 3). Pulmonary flow measured in the main pulmonary artery also correlated well with right ventricular stroke volume (Spearman’s rho = 0.972). Relative to the main pulmonary artery, measurements at pulmonary valve and pulmonary branches overestimated flow by 0.15 l/min and 0.27 l/min, respectively (Fig. 3), while RVSV overestimated with 0.26 l/min. Bland-Altman, ranges, and biases are presented in Table 2.
Fig. 3

Pulmonary flow. Correlation and Bland-Altman plots of pulmonic flow measured at different levels using as reference the level of the main pulmonary artery. For each Bland-Altman plot, the average of measurements from both levels is plotted on the x-axis and the difference is plotted on the y-axis. The solid gray horizontal line plots the mean difference, and the dotted gray lines indicate the limits of agreement. PV pulmonary valve, MPA main pulmonary artery, RPA right pulmonary artery, LPA left pulmonary artery

Table 2

Consistency of flow measurements at different locations

 Level of measurementFlow (l/min) median (min–max)Spearman’s rhoaBland-Altman
Bias± 1.96 SD
Pulmonic flow
 Pulmonary valve8.6 (3.2–20.3)0.8860.148− 0.86 to 1.16
 Main pulmonary artery8.5 (4.4–20.2)
 Right + left pulmonary arteries8.7 (4.4–19.9)0.8850.266− 1.12 to 1.65
 Right ventricular stroke volumeb9.0 (4.6–20.0)0.972− 0.257− 2.01 to 1.49
Systemic flow
 Aortic valve5.2 (2.9–10.0)0.9910.135− 1.23 to 1.5
 Ascending aorta4.9 (2.7–10.7)
 SVCc + descending aorta4.7 (2.9–10.5)0.9740.169− 1.6 to 1.94
 Left ventricular stroke volumeb4.8 (3.0–8.2)0.9060.157− 2.45 to 2.1

Absolute blood flow measurements are consistent across multiple locations and with stroke volumes

SVC superior vena cava

aMain pulmonary artery and ascending aorta are taken as reference

bEight patients had more than 20% mitral or tricuspid regurgitation and were excluded from the analysis

cSVC measured above the azygos vein when visible

Pulmonary flow. Correlation and Bland-Altman plots of pulmonic flow measured at different levels using as reference the level of the main pulmonary artery. For each Bland-Altman plot, the average of measurements from both levels is plotted on the x-axis and the difference is plotted on the y-axis. The solid gray horizontal line plots the mean difference, and the dotted gray lines indicate the limits of agreement. PV pulmonary valve, MPA main pulmonary artery, RPA right pulmonary artery, LPA left pulmonary artery Consistency of flow measurements at different locations Absolute blood flow measurements are consistent across multiple locations and with stroke volumes SVC superior vena cava aMain pulmonary artery and ascending aorta are taken as reference bEight patients had more than 20% mitral or tricuspid regurgitation and were excluded from the analysis cSVC measured above the azygos vein when visible For systemic flow, median Qs is 4.9 l/min (2.7–10.7 l/min) at the ascending aorta level, 5.2 l/min (2.9–10.0 l/min) at the aortic valve level and 4.7 l/min (2.9–10.5 l/min) at the peripheral level. Median cardiac output measured from LVSV was 4.8 l/min (3.0–8.2 l/min). Similarly, the correlations between Qs measurements performed at different levels were classified as very strong (Spearman’s rho = 0.991–0.974) (Table 2, Fig. 4). Relative to the ascending aorta results, measurements at the aortic valve overestimated Qs with 0.14 l/min, and by 0.17 l/min at the peripheral level, while measurements of the LVSV underestimated Qs with 0.16 l/min (Fig. 4). Bland-Altman, ranges, and biases are presented in Table 2.
Fig. 4

Systemic flow. Correlation and Bland-Altman plots of systemic flow measurements at different levels and taking as reference the level of the ascending aorta. For each Bland-Altman plot, the average of measurements from both levels is plotted on the x-axis and the difference is plotted on the y-axis. The solid gray horizontal line plots the mean difference, and the dotted gray lines indicate the limits of agreement. AV aortic valve, AoAsc ascending aorta, AoD descending aorta, SVC superior vena cava

Systemic flow. Correlation and Bland-Altman plots of systemic flow measurements at different levels and taking as reference the level of the ascending aorta. For each Bland-Altman plot, the average of measurements from both levels is plotted on the x-axis and the difference is plotted on the y-axis. The solid gray horizontal line plots the mean difference, and the dotted gray lines indicate the limits of agreement. AV aortic valve, AoAsc ascending aorta, AoD descending aorta, SVC superior vena cava

Correlation of 4D flow shunt fraction measurements

Good correlation was found between Qp/Qs ratios derived at the main artery level and ratios derived at the valve and peripheral level (Spearman’s ρ = 0.95 for both comparisons), with smaller bias for the valve level vs. peripheral level (− 0.023 l/min vs. − 0.049 l/min, p = 0.922) (Supplementary Fig. 4). Bland-Altman, ranges, and biases are presented in Table 3. A threshold of 1.5 is often used as a threshold for ASD closure. In our cohort, 10 patients had ratios measuring below 1.5 at all levels, and 16 patients had shunt ratios measuring above 1.5 at all levels. In only three patients did we observe some measurements above and below the 1.5 threshold, and at all locations these measurements tended to stay close to 1.5 (range 1.3–1.7) (Fig. 5).
Table 3

Comparison of shunt fractions measured at different locations

Level of measurementShunt fraction median (min–max)Spearman’s rhoaBland-Altman
Bias± 1.96 SD
Valve1.6 (0.9–3.7)0.95− 0.023− 0.42 to 0.37
Main arterya1.6 (1.0–3.5)
Peripheral1.6 (0.8–3.9)0.95− 0.049− 0.47 to 0.37
Stroke volumeb1.8 (1.0–3.3)0.930.072− 0.57 to 0.71

aLevel of main arteries is taken as reference

bEight patients had more than 20% mitral or tricuspid regurgitation and were excluded from the analysis

Fig. 5

Distribution of atrial septal defect shunt fractions (Qp/Qs) measured at multiple levels. Qp/Qs at different locations ordered from high to low. A solid line is placed at the treatment threshold of 1.5 Qp/Qs. Arrows highlight the three patients in which the measurements at different levels are crossing the threshold line

Comparison of shunt fractions measured at different locations aLevel of main arteries is taken as reference bEight patients had more than 20% mitral or tricuspid regurgitation and were excluded from the analysis Distribution of atrial septal defect shunt fractions (Qp/Qs) measured at multiple levels. Qp/Qs at different locations ordered from high to low. A solid line is placed at the treatment threshold of 1.5 Qp/Qs. Arrows highlight the three patients in which the measurements at different levels are crossing the threshold line

Interobserver consistency of 4D flow, shunt fraction and volume measurements

Measurements of blood flow, shunt fraction and shunt volume with 4D flow were highly reproducible between two independent readers. Interobserver consistency for flow measurements was excellent at all levels, showing ICCs all ≥ 0.955. Interobserver consistency for the calculated shunt fraction showed ICCs ≥ 0.98 and for shunt volume ICCs ≥ 0.979. All ICCs for measurements of blood flow, calculated shunt fractions (Qp/Qs) and shunt volumes are displayed in Table 4.
Table 4

Comparison of flow measurements by independent observers

LevelSystemic flowPulmonary flowQp/QsShunt volume
Valve0.9680.9870.9830.989
Main artery0.9750.9860.9810.987
Peripheral0.9550.9810.9680.979

Intraclass coefficients (ICCs) for measurements of blood flow, calculated shunt fractions (Qp/Qs) and shunt volumes displayed

Comparison of flow measurements by independent observers Intraclass coefficients (ICCs) for measurements of blood flow, calculated shunt fractions (Qp/Qs) and shunt volumes displayed

Direct versus indirect 4D shunt volume measurements

In 20/29 patients (69%), it was feasible to obtain direct shunt volumes at the exact location of the septal defect. Correlations between direct and indirect (Qp–Qs) measurements were classified as very strong (Spearman’s ρ = 0.96). However, shunt volume was underestimated by 0.57 l/min using direct measurements. Bland-Altman, ranges and standard deviation are presented in Table 5. Two of these patients had multiple ASDs, but some small ASDs did not allow for direct flow measurement (Supplementary Fig. 5).
Table 5

Comparison of shunt volume measured at the atrial septal level against measurement at the main artery level

Level of measurementShunt volume (l/min) median (min–max)Spearman’s rhoBland-Altman
Bias (l/min)± 1.96 SD
Atrial septum2.95 (0.2–8.7)0.955− 0.57− 2.71 to 1.57
Main artery3.6 ( − 0.2 to 1.8)

∞Direct measurement of ASD was feasible in 20 patients

†Level of main arteries is taken as reference

Comparison of shunt volume measured at the atrial septal level against measurement at the main artery level ∞Direct measurement of ASD was feasible in 20 patients †Level of main arteries is taken as reference

Discussion

We show in this study that 4D flow MRI can be sufficient for evaluation of patients with ASD, including quantification of shunt fraction, and can be robustly performed at multiple institutions; 4D flow MRI is consistent and reliable for measuring systemic and pulmonic blood flow and obtaining shunt fractions at multiple levels across the vascular tree. In daily practice, a shunt fraction (Qp/Qs) threshold above 1.5 is often used as a critical parameter to determine the need for ASD closure. By 4D flow MRI, few patients had mixed results near the 1.5 threshold. In those patients, other clinical features may be used to decide upon individual surgical or medical management, such as right heart chamber enlargement or pulmonary pressure [2, 5]. In this study, direct shunt volume quantification was obtained at the level of ASD by tracking the atrial septum frame by frame throughout the cardiac cycle. Direct shunt volume quantification was feasible in 69% of the patients and correlated well with calculated shunt volumes obtained by 4D flow measurements at the level of main arteries (Qp–Qs) (r = 0.955). Tracking the atrial septum may be challenging if there is insufficient image quality, if the size of the ASD is small or if there are multiple ASDs. For example, in two patients the direct quantification value was lower than the indirect quantification. When these cases were further reviewed, we found additional shunts, which were missed in the initial analysis (Supplementary Fig. 5). Therefore, we believe that direct quantification of each ASD can be helpful to determine whether all of shunts have been appropriately accounted for. Mismatch between direct and indirect measurements may point to additional undetected shunts. We show in the current study that it is possible to achieve excellent multilevel and interreader reproducibility with 4D flow MRI at multiple centers. This alleviates some previous concerns that 4D flow might only be achievable at one or two centers with extensive experience. This is further supported by recent studies showing good scan-rescan reproducibility and good intraobserver agreement with 4D flow [23, 24]. We further show here that experienced readers are not necessarily required to achieve high reproducibility. In addition, we demonstrate here that 4D flow can enable measurement of shunts at multiple alternative locations. This is especially helpful in the case of turbulent flow, aliasing or metallic artifacts. The 4D flow measurements can be performed at an alternative location distant to such artefacts to answer the clinical question. In patients with BAV, for example, flow acceleration across the aortic valve [25] can compromise the accuracy of measurements in areas of turbulent flow [26, 27], and an alternate measurement may be more accurate. We present the current work, recognizing that 4D flow is an evolving imaging technique [28, 29] and new strategies are being developed, including incorporation of multiple velocity encoding speeds [30, 31]. To date, 4D flow has shown its potential for evaluation of congenital heart disease [32], and is being introduced in daily clinical practice for other clinical indications [33]. Additional work may be required to assess the performance of 4D flow in specific clinical scenarios. In the current work, we did not explore a direct comparison to other advanced imaging techniques, which can also be used to assess shunt fraction. For example, Yamasaki et al. propose CT as an approach for quantification of ASD [34], obtaining ventricular stroke volumes from finely detailed anatomic data. However, without flow information provided by 4D flow or echocardiography, this approach may be confounded by concomitant valve regurgitation.

Limitations

We recognize a few potential limitations of the study. The patient population was not large, but we believe sufficient to demonstrate the robustness of the method. Second, although it is a study across multiple centers, all 4D flow acquisitions were performed using equipment from a single vendor. Additional work may be required to confirm similar quality 4D flow measurements can be obtained on other platforms. Third, a gadolinium-based contrast agent was used prior to image acquisition at all sites. Further work is needed to determine whether similar results can be obtained without intravenous contrast. In addition, we did not perform a direct comparison against 2D phase-contrast MRI in this study. We did find that flow measurements were consistent with stroke volumes obtained from anatomical data, which was reassuring. Multiple previous studies have compared 4D flow and 2D phase-contrast measurements, showing that measurements from each technique are generally consistent [35, 36]. Bollache and colleagues showed better correlation between 4D flow and three-direction-velocity 2D phase-contrast than with the one-direction-velocity 2D phase-contrast technique, which is the most commonly used clinical technique [36].

Conclusions

For patients referred for evaluation of ASD, 4D flow MRI showed excellent multilevel and interreader reproducibility for systemic and pulmonary blood flow measurements and shunt quantification obtained at different levels throughout the vascular tree. Below is the link to the electronic supplementary material. Figure 1 Supplementary. Reconstruction planes. Long- a and short-axis b views of the atrial cavities were used to evaluate the presence of ASD. Ra right atria, rv right ventricle, la left atria, lv left ventricle, SVC superior vena cava (JPEG 1549 kb) Figure 2 Supplementary. Classification of ASD subtypes. ASD secundum a can easily be identified as it is centered in the atrial septum. ASD primum b is typically located near the ventricles as it is a type of atrioventricular defect, and the associated mitral cleft can lead to mitral regurgitation. Sinus venous ASD c is located more cranially at the connection of SVC and RA. Unroofed coronary sinus d can be detected as a connection between the LA and coronary sinus. Ra right atrium, rv right ventricle, la left atrium, lv left ventricle, SVC superior vena cava (JPEG 2982 kb) Figure 3 Supplementary. Chart of patient inclusion and measurements performed (JPEG 1633 kb) Figure 4 Supplementary. Shunt fractions (Qp/Qs) measured at different levels. Correlations and Bland-Altman plots of the Qp/Qs fractions, taking as reference the Qp/Qs at the level of main arteries. For each Bland-Altman plot, the average of fractions from both levels is plotted on the x-axis and the difference is plotted on the y-axis. The solid gray horizontal line plots the mean difference, and the dotted gray lines indicate the limits of agreement (JPEG 2982 kb) Figure 5 Supplementary. Example of a patient with multiple ASDs. A 48-year-old female patient with four ASDs as identified using 4D flow MRI (presented short axes, a–b). One large and three small ASDs were detected (arrows). La left atrium, ra right atrium, 1–4 the ASD numbers (JPEG 1433 kb)
  34 in total

1.  4D phase-contrast flow cardiovascular magnetic resonance: comprehensive quantification and visualization of flow dynamics in atrial septal defect and partial anomalous pulmonary venous return.

Authors:  Israel Valverde; John Simpson; Tobias Schaeffter; Philipp Beerbaum
Journal:  Pediatr Cardiol       Date:  2010-09-17       Impact factor: 1.655

2.  Quantitative 2D and 3D phase contrast MRI: optimized analysis of blood flow and vessel wall parameters.

Authors:  A F Stalder; M F Russe; A Frydrychowicz; J Bock; J Hennig; M Markl
Journal:  Magn Reson Med       Date:  2008-11       Impact factor: 4.668

3.  Multi-VENC acquisition of four-dimensional phase-contrast MRI to improve precision of velocity field measurement.

Authors:  Hojin Ha; Guk Bae Kim; Jihoon Kweon; Young-Hak Kim; Namkug Kim; Dong Hyun Yang; Sang Joon Lee
Journal:  Magn Reson Med       Date:  2015-06-08       Impact factor: 4.668

4.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

5.  Reproducibility and interobserver variability of systolic blood flow velocity and 3D wall shear stress derived from 4D flow MRI in the healthy aorta.

Authors:  Pim van Ooij; Alexander L Powell; Wouter V Potters; James C Carr; Michael Markl; Alex J Barker
Journal:  J Magn Reson Imaging       Date:  2015-07-03       Impact factor: 4.813

6.  Rapid pediatric cardiac assessment of flow and ventricular volume with compressed sensing parallel imaging volumetric cine phase-contrast MRI.

Authors:  Albert Hsiao; Michael Lustig; Marcus T Alley; Mark Murphy; Frandics P Chan; Robert J Herfkens; Shreyas S Vasanawala
Journal:  AJR Am J Roentgenol       Date:  2012-03       Impact factor: 3.959

Review 7.  4D flow magnetic resonance imaging: role in pediatric congenital heart disease.

Authors:  Claire M Lawley; Kathryn M Broadhouse; Fraser M Callaghan; David S Winlaw; Gemma A Figtree; Stuart M Grieve
Journal:  Asian Cardiovasc Thorac Ann       Date:  2017-02-10

8.  Venous and arterial flow quantification are equally accurate and precise with parallel imaging compressed sensing 4D phase contrast MRI.

Authors:  Umar Tariq; Albert Hsiao; Marcus Alley; Tao Zhang; Michael Lustig; Shreyas S Vasanawala
Journal:  J Magn Reson Imaging       Date:  2012-11-21       Impact factor: 4.813

9.  Whole-heart four-dimensional flow can be acquired with preserved quality without respiratory gating, facilitating clinical use: a head-to-head comparison.

Authors:  Mikael Kanski; Johannes Töger; Katarina Steding-Ehrenborg; Christos Xanthis; Karin Markenroth Bloch; Einar Heiberg; Marcus Carlsson; Håkan Arheden
Journal:  BMC Med Imaging       Date:  2015-06-18       Impact factor: 1.930

10.  In-scan and scan-rescan assessment of LV in- and outflow volumes by 4D flow MRI versus 2D planimetry.

Authors:  Vivian P Kamphuis; Roel L F van der Palen; Patrick J H de Koning; Mohammed S M Elbaz; Rob J van der Geest; Albert de Roos; Arno A W Roest; Jos J M Westenberg
Journal:  J Magn Reson Imaging       Date:  2017-06-22       Impact factor: 4.813

View more
  6 in total

1.  4D Flow MRI Quantification of Congenital Shunts: Comparison to Invasive Catheterization.

Authors:  Michael J Horowitz; Daniel F Kupsky; Howaida G El-Said; Laith Alshawabkeh; Seth J Kligerman; Albert Hsiao
Journal:  Radiol Cardiothorac Imaging       Date:  2021-04-01

2.  4D Flow Vorticity Visualization Predicts Regions of Quantitative Flow Inconsistency for Optimal Blood Flow Measurement.

Authors:  Francisco J Contijoch; Michael Horowitz; Evan Masutani; Seth Kligerman; Albert Hsiao
Journal:  Radiol Cardiothorac Imaging       Date:  2020-02-27

3.  Feasibility and validation of trans-valvular flow derived by four-dimensional flow cardiovascular magnetic resonance imaging in pacemaker recipients.

Authors:  Christopher E D Saunderson; Maria F Paton; Amrit Chowdhary; Louise A E Brown; John Gierula; Anshuman Sengupta; Christopher Kelly; Pei G Chew; Arka Das; Thomas P Craven; Rob J van der Geest; David M Higgins; Liang Zhong; Klaus K Witte; John P Greenwood; Sven Plein; Pankaj Garg; Peter P Swoboda
Journal:  Magn Reson Imaging       Date:  2020-09-02       Impact factor: 2.546

4.  Left ventricular global longitudinal strain in bicupsid aortic valve patients: head-to-head comparison between computed tomography, 4D flow cardiovascular magnetic resonance and speckle-tracking echocardiography.

Authors:  Allard T van den Hoven; Sultan Yilmazer; Raluca G Chelu; Roderick W J van Grootel; Savine C S Minderhoud; Lidia R Bons; An M van Berendoncks; Anthonie L Duijnhouwer; Hans-Marc J Siebelink; Annemien E van den Bosch; Ricardo P J Budde; Jolien W Roos-Hesselink; Alexander Hirsch
Journal:  Int J Cardiovasc Imaging       Date:  2020-05-25       Impact factor: 2.357

5.  Pathology and Advanced Imaging-Characterization of a Congenital Cardiac Defect and Complex Hemodynamics in a Pig: A Case Report.

Authors:  Alexandra J Malbon; Miriam Weisskopf; Lukas Glaus; Sebastian Neuber; Maximilian Y Emmert; Christian T Stoeck; Nikola Cesarovic
Journal:  Front Vet Sci       Date:  2021-12-06

6.  Kat-ARC accelerated 4D flow CMR: clinical validation for transvalvular flow and peak velocity assessment.

Authors:  Hosamadin Assadi; Bhalraam Uthayachandran; Rui Li; James Wardley; Tha H Nyi; Ciaran Grafton-Clarke; Andrew J Swift; Ana Beatriz Solana; Jean-Paul Aben; Kurian Thampi; David Hewson; Chris Sawh; Richard Greenwood; Marina Hughes; Bahman Kasmai; Liang Zhong; Marcus Flather; Vassilios S Vassiliou; Pankaj Garg
Journal:  Eur Radiol Exp       Date:  2022-09-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.